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Ulster Medical Society rooms,  
Whitla Medical Building, Belfast 
PROGRAMME
Of  the  submissions,  the  following  5  were  shortlisted  for  platform 
presentations:
1.  Chronic Kidney Disease associated with mortality in Northern Ireland 
- Dr M Quinn
2.   Metformin, Chronic Kidney Disease and Lactic Acidosis: Is metformin 
absolutely contraindicated? - Dr MC McCloskey
3.  Folic Acid  use  and  major  congenital  malformations  in  offspring  of 
women with epilepsy. A prospective study from The UK Epilepsy and 
Pregnancy Register - Dr SJ Hunt
4.   Indications for Revision Total Hip Replacement in Northern Ireland  - Dr 
Ciara Stevenson
5.   Randomised Controlled Trial to assess the vascular and biochemical 
effects of Cilostazol in patients with peripheral arterial disease - Mr M 
O’Donnell
The following 16 were shortlisted for poster presentations:
1.   Transient Cardiomyopathy as presenting feature of Acute Disseminated 
Encephalomyelitis - Dr E Mawhinney
2.   Posterior Leucoencephalopathy Syndrome in a post-partum patient - Dr 
KM McKnight
3.   An audit of intravenous immunoglobulin use in the NI Neurology 
Department - Dr E Devenney
4.   Usefulness of a District General Neurologist in the diagnosis of non-
organic illness - Dr A Fitzpatrick
5.   Octreotide scanning in the detection of metastatic renal cell carcinoma 
- Dr MC McCloskey
6.   Carbon Monoxide Poisoning - Dr A Hammond
7.   Radical Trachelectomy: a case series - Dr N Ratnavelu
8.   Are alcohol related acute surgical admission rates falling? - Dr GJ 
Fitzmaurice 
9.   Improving outcomes in squint surgery - Dr MK O’Gallagher
10.  Management of hypoglycaemia in Intensive Care: a prospective audit 
- Dr Lloyd Turbitt
11.   The two-week rule help or hindrance? - Dr RS McCain
12.   The documentation, interpretation and management of abnormal fetal 
heart rates in labour - Dr M McCauley
13.  Indolent thyroid metastasis from renal cell carcinoma presenting after 
a remarkable 24 year latency following nephrectomy - Dr G McLean
14.  Accuracy and role of ultrasonography in assessing shoulder pathology 
- Dr KW Chan
15.  Analgesia and function following subacromial decompression - Dr J 
Campbell
16.  The effect of modernising medical careers on junior medical doctor 
personality, anxiety and career choice - Mr M O’Donnell
The winner of the platform, poster and the remaining platform abstracts are 
published below: 
PLATFORM PRESENTATION WINNER: 
ChRONIC kIdNEy dISEASE ASSOCIATEd WITh MORTALITy 
IN NORThERN IRELANd
M Quinn1, C Cardwell2, G Savage2, AP Maxwell1, F Kee2, D Fogarty1
Departments of  1Nephrology, and  2Public Health and Epidemiology, The 
Queen’s University of Belfast
Introduction: We investigated the association between chronic kidney disease 
(CKD) and mortality in Northern Ireland (NI). 
Methods: All creatinine results in NI between 1st Jan 2001 - 31st Dec 2002 
were  collected  and  linked  to  a  patient  database.  Estimated  glomerular 
filtration rates (eGFR) were calculated using the 4 variable modified diet in 
renal disease equation. The Registrar Generals office provided all cause and 
cardiovascular mortality follow up through to 31st Dec 2006.
Results: 2,065,694 creatinine results from 585,566 patients were collected. 
60,209 deaths occurred. Using eGFR as time varying covariate in a Cox 
survival model the following association between CKD and mortality was 
demonstrated.
Adjusted† hazard ratios (CI 95%) for mortality
eGFR
   > 60 ml/min/1.73m2
45 - 59 ml/min/1.73m2
30 - 44 ml/min/1.73m2
15 - 29 ml/min/1.73m2  
   < 15 ml/min/1.73m2






   Cardiovascular 





†Adjusted for Age and Sex 
Conclusions: This study demonstrates a graded association between CKD 
and mortality in the tested NI population. Having previously calculated the 
prevalence of CKD (eGFR < 60 ml/min/1.73m2) in NI as 3.69%1; this work 
indicates the clinical and public health importance of CKD. 
REFERENCE:
1.   Quinn, MP, Rainey A, Cairns KJ et al. The practical implications of using 
standardized estimation equations in calculating the prevalence of chronic 
kidney disease. Nephrol Dialysis Transplantation 2008;23(2):542-548.© The Ulster Medical Society, 2009.
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PLATFORM PRESENTATION RUNNERS UP:
METFORMIN, ChRONIC kIdNEy dISEASE, ANd 
LACTIC ACIdOSIS: IS METFORMIN AbSOLUTELy 
CONTRAINdICATEd?
MC McCloskey, J Smyth, W Marshall, N Leonard
Renal Unit, Ulster Hospital, Dundonald, Belfast, Northern Ireland
Aims: The  UK  prospective  diabetes  study  showed  that  metformin  was 
associated  with  a  lower  mortality  from  cardiovascular  disease  than 
sulphonylureas or insulin in obese patients with type 2 diabetes mellitus, 
as well as reduced all cause mortality.  However, concerns remain about its 
side effects, especially the perceived risk of lactic acidosis in the presence 
of chronic kidney disease (CKD). This may result in many patients with 
type 2 diabetes being denied metformin therapy1,2. We aimed to assess the 
incidence of metformin induced lactic acidosis over a seven year period, 
within our hospital.
Methods:  Data  was  retrieved  from  a  computerised  database,  laboratory 
records and individual case note review for patients admitted over a 7-year 
period,  from  01/01/2000  until  31/12/2006.  Diagnostic  codes  searched 
included metabolic acidosis, lactic acidosis, metformin, or glucophage. Renal 
function at presentation, at baseline, and the presence of a clearly identified 
precipitating illness were recorded (N = 205 401).
Results: Three cases of lactic acidosis in patients prescribed metformin were 
identified.  Each case had a precipitating illness; dehydration secondary to 
gastroenteritis in 2 cases and urinary sepsis in 1 case. Only one patient had 
baseline CKD (creatinine of 135mmol/l).
Discussion: The incidence of metformin induced lactic acidosis reported in 
this study is significantly lower than predicted in the literature, which quotes 
an estimated incidence of 0 – 0.09 cases per 1000 pt years1,2. 
A  Cochrane  review  of  206  comparative  trials  and  cohort  studies  in 
patients with type 2 diabetes who were treated with metformin and had no 
contraindications to its use, found no evidence of increased risk of developing 
fatal/non-fatal lactic acidosis in metformin treated patients.  They also found 
no difference in lactate concentrations between metformin and non-biguanide 
treated patients.  Several reports found that physicians have increasingly 
ignored contraindications to prescribing metformin and yet the incidence 
of lactic acidosis has remained very low.  The majority of case reports 
relating metformin to lactic acidosis report at least one other disease/acute 
illness that could result in lactic acidosis1,2. In our analysis each case had a 
precipitating illness.
Metformin  provides  a  greater  degree  of  cardiovascular  protection  than 
expected from antihyperglycaemic actions alone, and is the drug of choice 
for persons with type 2 diabetes. Further studies are required in order to 
accurately quantify the risk, if any, of metformin induced lactic acidosis in 
persons with CKD1,2.
REFERENCES:
1.  Jones  et  al.    Contraindications  to  the  use  of  metformin.    BMJ 
2003;326(7379):4 
2.   Tahrani et al. Metformin, heart failure, and lactic acidosis: is metformin 
absolutely contraindicated? BMJ 2007;335:508-512.
FOLIC ACId USE ANd MAjOR CONGENITAL 
MALFORMATIONS IN OFFSPRING OF WOMEN WITh 
EPILEPSy. A PROSPECTIvE STUdy FROM ThE Uk EPILEPSy 
ANd PREGNANCy REGISTER.
SJ Hunt, AJ Russell, WH Smithson, L Parsons, I Robertson, R Waddell, B 
Irwin, PJ Morrison, JJ Craig, JI Morrow 
Objective:  In  the  general  population  folic  acid  supplementation  during 
pregnancy has been demonstrated to reduce the frequency of major congenital 
malformations (MCMs) such as neural tube defects (NTDs). Women with 
epilepsy contemplating pregnancy are advised to take supplemental folic acid 
due to the known anti-folate effect of some anti-epileptic drugs
(AEDs). Here we aim to determine effectiveness of this practice.
Methods:  Prospective,  observational,  registration  and  follow-up  study. 
Cases are women with epilepsy who become pregnant and who are referred 
before outcome of the pregnancy is known. The main outcome measure is 
the MCM rate. 
Results: In 1,935 cases reported to have received pre-conceptual folic acid, 
76 MCMs (3.9%;95% C.I. 3.1 - 4.9%) and eight NTDs (0.4%; 95% C.I. 0.2 
- 0.8) were identified. For 2,375 women who were reported to have received 
folic acid but not until later in the pregnancy (n= 1,825) or not at all (n=550) 
there were 53 outcomes with an MCM (2.2%; 95% C.I. 1.7 - 2.9%) and eight 
NTDs (0.34%; 95% C.I. 0.2 - 0.7).
Conclusions: Extrapolation from studies carried out in the general population 
to groups of women with epilepsy may be questionable. The increased risk 
of MCM recorded in this group may occur through mechanisms other than 
that of folic acid metabolism.
INdICATIONS FOR REvISION TOTAL hIP REPLACEMENT IN 
NORThERN IRELANd 
CM Stevenson, BM Hanratty, MG McAlinden  
Ulster Hospital Belfast 
Within  Northern  Ireland  we  have  investigated  the  indications  for 
revision  hip  procedures,  carried  out  from  April  2006  to 
March  2007.  This  was  to  establish  our  indications  for  revision 
surgery  and  if  these  are  comparable  to  other  national  registers.   
An audit of all hospitals that perform revision surgery was carried out and the 
indications for revision procedures established. Revision procedures included 
replacement of one or both components, application of acetabular augmentation 
devices, and open reduction and internal fixation of peri-prosthetic fractures.   
180  patients  were  identified  in  six  hospitals.  Revisions  were  performed 
for a peri-prosthetic fracture in 38 (21%), infection in 12 (7%), recurrent 
dislocation  in  23(13%)  and  in  failure  of  implants  in  107  (59%). 
Six  hospitals  in  Northern  Ireland  (population  1.7  million)  carry 
out  revision  hip  surgery.  The  largest  body  of  information  on 
revision  hip  surgery  is  the  Swedish  Hip  Registry.  Their  incidence 
for  revision  hip  surgery  is  7%.  Their  indications  were:  aseptic 
loosening  71%,  infection  7.5%,  fracture  5.6%  and  dislocation  4.8%.   
Our data indicate a greater prevalence of revision for recurrent dislocation 
(13%versus 4.8%), and peri-prosthetic fractures (21% versus 5.6%) than the 
Swedish data. Further work should aim to identify any remediable surgical 
factors, which account for these differences 
RANdOMISEd CONTROLLEd TRIAL TO ASSESS ThE 
vASCULAR ANd bIOChEMICAL EFFECTS OF CILOSTAzOL IN 
PATIENTS WITh PERIPhERAL ARTERIAL dISEASE
ME O’Donnell1, SA Badger1, MA Sharif1, RR Makar1, IS Young2, LL Lau1, 
B Lee1, RJ Hannon1, CV Soong1.
Department of Vascular and Endovascular Surgery, Belfast City Hospital1 
and Department of Medicine, Queen’s University Belfast2, Northern Ireland.
Objectives: Cilostazol improves walking distance. The study aimed to assess 
vascular and biochemical effects of cilostazol in peripheral arterial disease 
(PAD) patients. 
Methods: Patients were randomised in a double-blinded, placebo-controlled 
trial. Baseline clinical data were recorded following medical optimisation. 
Clinical assessment included ankle-brachial index (ABI), arterial compliance, 
peripheral trancutaneous oxygenation (TCO2) and treadmill walking distance. 
Glucose homeostasis was assessed by fasting serum glucose and glycosylated 
haemoglobin levels along with lipid profiles. Quality of life (QoL) indices 
were recorded using the VascuQoLÒ questionnaire. All tests were at baseline, 
6- and 24-weeks.   
Results: 106 PAD patients (M=73) were recruited from December 2004 to 
January 2006 (median age:66.5, range 37-86). Patients in both treatment 
limbs  had  similar  baseline  demographics,  medical  co-morbidities  and 
walking performance. Patients who received cilostazol demonstrated a mean 
percentage improvement, in absolute claudication distance (77.2%vs.26.6% 
at 6-weeks and 161.7%vs.79.0% at 24-weeks, p<0.05). Arterial compliance 
improved at 6-weeks (-28.8%vs.-11.0%,p=0.005) and 24-weeks (-21.0%vs.-
11.5%,p=0.012).  There  was  no  difference  in  ABI,  TCO2  or  glucose 
homeostasis. Cilostazol reduced triglycerides at 6-and 24-weeks (p<0.002). 
Activity, symptom, pain, emotion and total VascuQoL indices improved in 
the cilostazol group at 24-weeks (p<0.03). © The Ulster Medical Society, 2009.
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Conclusions:  Maximal  walking  distance  was  improved  by  cilostazol  in 
PAD patients with further beneficial effects in arterial compliance, lipid 
homeostasis and QoL.
POSTER PRESENTATION WINNER
ThE “TWO-WEEk-RULE”; hELP OR hINdRANCE?
RS McCain, J Newell, SA Badger, RJ Kennedy, SJ Kirk.
Breast Surgery Unit, Ulster Hospital, Dundonald
Introduction: Breast cancer is a common malignancy. Department of Health 
guidelines state that all patients with suspected breast cancer should be 
referred urgently and seen by a specialist within two weeks of referral. The 
aim of this study was to assess referral patterns and clinical findings in 
patients referred to a specialist breast clinic within this context.
Methods: A prospective database was maintained for consecutive patients 
referred to a specialist breast clinic. Clinical findings in primary care and at 
the breast clinic were recorded and correlated with final diagnoses. 
Results: Data were collected on 1098 patients. 588 (54%) were referred 
urgently, 285 (26%) routinely and 225 (20%) were unspecified.  In many 
cases, referrals did not adhere to the “two-week-rule” guidelines. 86 patients 
(8%) were diagnosed with breast cancer. 72 (84%) of these were referred 
urgently, 6 (7%) routinely and 8 (9%) unspecified. Examination findings in 
primary and secondary care correlated in 487 (46%) patients.
Conclusions: A large number of sub-optimal referrals were made.  Sensitivity 
and specificity of clinical examination in primary care was low. Nonetheless, 
with excellent examination and diagnostic skills, sensitivity of the two-week-
rule could only reach 86%, suggesting that either the concept of urgent 
referral criteria or the criteria themselves are flawed.